Drug Target Review

JANUARY 14, 2025

In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry. Nina Truter Nina Truter is a translational scientist with a deep focus on understanding mechanisms of action in drug development and leveraging disparate datasets in biotech.

Drugs 69

Drugs Protein Expression Science Research 69

Drug Target Review

DECEMBER 6, 2024

In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry. For more: [link] ; [link] ; [link] ; [link] Nina Truter Nina Truter is a translational scientist with a deep focus on understanding mechanisms of action in drug development and leveraging disparate datasets in biotech.

RNA 52

RNA Drugs Research Science 52

Drug Target Review

DECEMBER 14, 2023

The new understanding may result in novel cancer therapies. She continued: “Now that we know more about this pathway, scientists could, in theory, produce a drug that could disrupt key pieces of the pathway in cancer cells, as opposed to using conventional chemotherapies that destroy healthy cells along with the cancer.”

DNA 59

DNA Clinical Trials Treatment Research 59

The Pharma Data

DECEMBER 15, 2020

NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Approval demonstrates our ability to execute upon the entirety of the drug development and registration process.

FDA Approval 52

FDA Approval Treatment FDA Therapies 52

Drug Target Review

FEBRUARY 14, 2025

In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry. For more: [link] ; [link] ; [link] ; [link] Nina Truter Nina Truter is a translational scientist with a deep focus on understanding mechanisms of action in drug development and leveraging disparate datasets in biotech.

Drugs 52

Drugs Research Immune Response Science 52

PLOS: DNA Science

OCTOBER 17, 2024

The first-ever approval of a safe and effective drug option will undoubtedly support the essential medical needs of those suffering.” ” Miplyffa is the first drug developed to treat NPD3 specifically. The new drug is taken with miglustat , which FDA approved for use in NPD3 in 2009.

Disease 52

Disease FDA Approval Drugs Treatment 52

NIH Director's Blog: Drug Development

MAY 21, 2020

Just one infusion of this combination antibody therapy lowered the amount of viral genetic material in the animals’ lungs by as much as 30 percent compared to the amount in untreated animals. Meanwhile, there’s been other impressive recent progress towards the development of monoclonal antibody therapies for COVID-19.

Virus 52

Virus Vaccine Laboratories Small Molecule 52